Acura Pharmaceuticals Inc., of Palatine, Ill., said its universal shelf registration statement on form S-3, as amended, was declared effective by the SEC and permits the company to offer and sell, from time to time, up to $63.8 million of equity, debt or other types of securities.

Aeglea Biotherapeutics Inc., of Austin, Texas, set terms for its planned IPO and said it will offer 3.5 million shares of common stock priced in the range $16 10 $18 per share. Established in 2013, Aeglea raised $44 million in a series B round last year to support initial clinical work testing its amino acid-degrading approach in both a rare disease indication and cancer. The company disclosed in its S-1A filing that lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat two extremes of arginine metabolism, including arginine excess in patients with arginase I deficiency, as well as some cancers which have been shown to have a metabolic dependence on arginine. It will list its stock on Nasdaq under the symbol AGLE. (See BioWorld Today, March 24, 2015.)

Anacor Pharmaceuticals Inc., of Palo Alto, Calif., said it intends to offer $250 million of convertible senior notes due 2023 in a private placement. It also intends to grant to the initial purchasers of the notes a 30-day option to purchase up to an additional $37.5 million of the notes.

Vitae Pharmaceuticals Inc., of Fort Washington, Pa., said it completed its underwritten public offering of 5.83 million shares of its common stock at $6 each. The company has granted the underwriters a 30-day option to purchase up to an additional 875,000 shares of its common stock on the same terms and conditions. Piper Jaffray & Co. and BMO Capital Markets Corp. acted as joint book-running managers for the offering. Wedbush Pacgrow acted as co-manager.